Publications by authors named "Bayan Abd Elkader"
Vaccination against COVID-19 and influenza provides the best defense against morbidity and mortality. Administering both vaccines concurrently may increase vaccination rates and reduce the burden on the healthcare system. This study evaluated the immunogenicity of healthcare workers in Israel who were co-administered with the Omicron BA.
View Article and Find Full Text PDFBackground: Defining immune correlates of protection against COVID-19 is pivotal for optimizing the use of COVID-19 vaccines, predicting the impact of novel variants on clinical outcomes, and advancing the development of immunotherapies and next-generation vaccines. We aimed to identify vaccine-induced immune correlates of protection against COVID-19-related hospitalizations in a highly vaccinated heart transplant (HT) cohort.
Methods: In a case-control study of HT recipients vaccinated with the BNT162b2 vaccine, patients were prospectively assessed for vaccine-induced neutralization of the wild-type virus, and the Delta and Omicron BA.
In 2022, the antigenically divergent SARS-CoV-2 omicron variants (BA.1, BA.2, BA.
View Article and Find Full Text PDFObjectives: The capability of the SARS-CoV-2 Omicron variant to escape immunity conferred by mRNA vaccines has led to the development of Omicron-adapted vaccines. In this study, we aimed to compare the immune response with the ancestral strain and with the BA.1 Omicron variant after administration of the original vaccine and the Omicron-adapted vaccine.
View Article and Find Full Text PDFWe evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.
View Article and Find Full Text PDFArticle Synopsis
- This study assessed the neutralising antibody levels in healthcare workers who had a breakthrough BA.1 infection after being vaccinated multiple times against SARS-CoV-2 and its Omicron variants.
- Individuals who had three or four vaccine doses before infection showed enhanced neutralising antibodies against the original WT virus after the Omicron breakthrough.
- The research suggests that a fourth vaccine dose might not significantly boost neutralising effectiveness against newer Omicron variants (BA.4 and BA.5), indicating a potential need for an Omicron-specific vaccine.